


Remarks

The communication mailed March 26, 2002 has been received and reviewed. The application is to be amended as set forth. All amendments and claim cancellations are made without prejudice or disclaimer.

The application was subjected to a restriction requirement. Applicants elect the invention of Group I and cancel the non-elected claims.

Respectfully submitted,



Allen C. Turner
Registration No. 33,041
Attorney for Applicants
Trask Britt, PC
P. O. Box 2550
Salt Lake City, Utah 84110
Telephone: (801) 532-1922

Date: May 14, 2002

VERSION SHOWING CHANGES MADE

3. (Twice amended) [A] The peptide [according to] of claim 1 comprising at least two coupled GnRH decapeptide sequences, wherein at least one of the amino acids of said coupled GnRH decapeptide sequences is replaced by a different amino acid.

4. (Twice amended) [A] The peptide [according to] of claim 1, wherein said different amino acid is Ala.

5. (Twice amended) [A] The peptide [according to] of claim 1 wherein said peptide is selected from the group consisting of:

SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

10. (Twice amended) A vaccine comprising [a] the peptide [in accordance with] of claim 1.

11. (Twice amended) [A] The vaccine [according to] of claim 10, further comprising an adjuvant.

12. (Twice amended) [A] The vaccine [according to] of claim 11, wherein said adjuvant is an oil phase of an emulsion selected from the group consisting of a water-in-oil emulsion and a double oil emulsion.

15. (Twice amended) [A] The vaccine [according to] of claim 10 that is sufficiently active for administration in a single dose for the essential immunocastration of pigs.

20. (Twice amended) A vaccine against GnRH-II comprising [a] the peptide [according to] of claim 1.

21. (Twice amended) Composition for the treatment of prostate cancer comprising [a] the peptide [according to] of 1.

26. (Amended) [A] The peptide [according to] of claim 3 wherein said different amino acid is Ala.

27. (Amended) [A] The peptide [according to claims] of claim 3 wherein said peptide is selected from the group consisting of:

SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

28. (Amended) [A] The peptide [according to claims] of claim 4 wherein said peptide is selected from the group consisting of:

SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7.

34. (Amended) A vaccine comprising [a] the peptide [in accordance with] of claim 1.

35. (Amended) A vaccine comprising [a] the peptide [in accordance with] of claim 3.

36. (Amended) A vaccine comprising [a] the peptide [in accordance with] of claim 5.

51. (Amended) A vaccine against GnRH-II comprising [a] the peptide [according to] of claim 5.

52. (Amended) Composition for the treatment of prostate cancer comprising [a] the peptide [according to] of claim 5.